Source: EURLEX
Language: en
Format: md

Judgment of the General Court (Eighth Chamber) of 20 December 2023 – Pharmaselect International and OmniActive Health Technologies v EUIPO – OmniActive Health Technologies and Pharmaselect International (LUTAMAX)

(Joined Cases T‑221/22 and T‑242/22) (
[1](#t-ECR_62022TJ0221_INF_EN_01-E0001)
)

(EU trade mark – Revocation proceedings – EU word mark LUTAMAX – Genuine use of the mark – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001) – Obligation to state reasons – Article 94(1) of Regulation 2017/1001)

| 1. | EU trade mark – Procedural provisions – Statement of reasons for decisions – First sentence of Article 94(1) of Regulation 2017/1001 – Scope identical to that of Article 296 TFEU – Recourse by the Board of Appeal to implicit reasoning – Whether permissible – Conditions  (Art. 296 TFEU; European Parliament and Council Regulation 2017/1001, Art. 94(1), first sentence)  (see paragraphs 27-29) |

| 2. | Action for annulment – Pleas in law – Lack of or inadequate statement of reasons – Separate plea in law from the one concerning substantive legality  (Art. 296 TFEU)  (see paragraph 30) |

| 3. | EU trade mark – Surrender, revocation and invalidity – Grounds for revocation – Lack of genuine use of the mark – Word mark LUTAMAX  (European Parliament and Council Regulation 2017/1001, Arts 18(1) and 58(1)(a))  (see paragraphs 46, 52-55) |

| 4. | EU trade mark – Surrender, revocation and invalidity – Grounds for revocation – Lack of genuine use of the mark – Proof of use – Partial use – Effect – Concept of ‘some of the goods or services covered by the registration’ – Independent subcategory of goods or services – Concept – Dietary supplements adapted for medical or dietetic use for supporting eye health – Not included  (European Parliament and Council Regulation 2017/1001, Art. 58(2))  (see paragraphs 61-65, 67, 69, 70, 72, 73) |

Operative part

The Court:

| 1. | Annuls point 2 of the operative part of the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 24 February 2022 (Joined Cases R 524/2021-1 and R 649/2021-1); |

| 2. | Dismisses the action in Case T‑221/22 as to the remainder; |

| 3. | Dismisses the action in Case T‑242/22; |

| 4. | Orders Pharmaselect International Beteiligungs GmbH, EUIPO and OmniActive Health Technologies Ltd to bear their own respective costs in Case T‑221/22; |

| 5. | Orders, in Case T‑242/22, OmniActive Health Technologies to bear its own costs and to pay the costs incurred by EUIPO and by Pharmaselect International Beteiligungs. |

---

(
[1](#c-ECR_62022TJ0221_INF_EN_01-E0001)
) [OJ C 237, 20.6.2022](./../../../legal-content/EN/AUTO/?uri=OJ:C:2022:237:TOC).

[Top](#document1)